GetTopicDetailResponse(id=a146939149e, topicName=達克替尼, introduction=達克替尼, content=null, image=null, comments=3, allHits=1067, url=https://h5.medsci.cn/topic?id=93914, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=76644, tagList=[TagDto(tagId=76644, tagName=達克替尼)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2018109, encodeId=aa872018109d1, content=<a href='/topic/show?id=a146939149e' target=_blank style='color:#2F92EE;'>#達克替尼#</a>, objectTitle=Brit J Cancer：達克替尼能夠抑制去勢難治性前列腺癌的惡化, objectType=article, longId=172239, objectId=7ef61e22396b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ef61e22396b, replyNumber=0, likeNumber=160, createdTime=2019-12-29, rootId=0, userName=lily1616, userId=8143398, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ef61e22396b, moduleTitle=Brit J Cancer：達克替尼能夠抑制去勢難治性前列腺癌的惡化, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=7ef61e22396b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2018108, encodeId=045a20181084d, content=<a href='/topic/show?id=a146939149e' target=_blank style='color:#2F92EE;'>#達克替尼#</a>, objectTitle=FDA批準輝瑞EGFR抑制劑達克替尼用于EGFR突變的局部晚期或轉移性NSCLC患者的一線治療, objectType=article, longId=149971, objectId=bdf71499e193, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdf71499e193, replyNumber=0, likeNumber=81, createdTime=2018-10-25, rootId=0, userName=lily1616, userId=8143398, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdf71499e193, moduleTitle=FDA批準輝瑞EGFR抑制劑達克替尼用于EGFR突變的局部晚期或轉移性NSCLC患者的一線治療, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=bdf71499e193)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2018107, encodeId=a5de201810eda, content=<a href='/topic/show?id=a146939149e' target=_blank style='color:#2F92EE;'>#達克替尼#</a>, objectTitle=JCO：達克替尼一線用于EGFR突變NSCLC患者，生存期達34.1個月（ARCHER 1050研究）, objectType=article, longId=141439, objectId=d96a141439e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d96a141439e2, replyNumber=0, likeNumber=75, createdTime=2019-06-05, rootId=0, userName=lily1616, userId=8143398, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d96a141439e2, moduleTitle=JCO：達克替尼一線用于EGFR突變NSCLC患者，生存期達34.1個月（ARCHER 1050研究）, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=d96a141439e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
